Essai Clinique

Généré le 19 mai 2024 à partir de

Titre	A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma
Protocole ID	EMERALD-3
ClinicalTrials.gov ID	NCT05301842
Type(s) de cancer	Foie
Phase	Phase III
Type étude	Clinique
Médicament	Durvalumab en association avec tremelimumab ± lenvatinib concomitant avec TACE comparé au TACE seul
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	
Investigateur principal	Dre Hélène Castel
Coordonnateur	Joannie Blanchette 514-890-8000 poste 36304
Statut	Actif en recrutement
Date d'activation	21-10-2022
But étude	A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab, tremelimumab and lenvatinib therapy in patients with locoregional hepatocellular carcinoma
Critères d'éligibilité	• No evidence of extrahepatic disease • Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE • Child Pugh score class A • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment • Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria • Adequate organ and marrow function
Critères d'exclusion	• History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia • History of hepatic encephalopathy • Major portal vein thrombosis visible on baseline imaging • Uncontrolled arterial hypertension • Co-infection with HBV and HDV